SAN DIEGO, California — September 3, 2025 — Leads & Copy — Illumina Inc. (NASDAQ: ILMN) has launched Illumina Protein Prep, an assay offering performance for next-generation sequencing (NGS)-based proteomics discovery at scale. Available to customers worldwide, it enables researchers to add proteomics to large-scale genomics studies and fuel insights across cancer, cardio metabolic, and immunologic diseases, with a sample-to-insights solution for discovery and clinical research.
Illumina Protein Prep can measure 9500 unique human protein targets. Combining it with Illumina NovaSeq sequencing platforms enables the interrogation of proteins in a single experiment. After sequencing, Illumina DRAGEN Protein Quantification and Connected Multiomics software turn proteomic data into insights.
Since 2024, Illumina has worked with collaborators to pilot Illumina Protein Prep. Data from an initial study showed a 7.5% increase in diagnostic yield.
Illumina Protein Prep is giving Couts’s research team a powerful, unbiased tool to interrogate these unique conditions. Other proteomic technologies the lab has used were limited to 92 proteins.
In January, Illumina announced a pilot proteomics program with UK Biobank and a consortium of biopharma collaborators to analyze 50,000 samples with Illumina Protein Prep.
In June, Illumina announced an agreement to acquire SomaLogic.
Contacts:
Investors: Illumina Investor Relations, 858-291-6421, IR@illumina.com
Media: Christine Douglass, PR@illumina.com
Source: Illumina Inc.
